Two FDA-Cleared PLAC® Tests

As pioneers in the testing of Lp-PLA2, a validated marker of cardiovascular risk, our portfolio of commercially-available PLAC® Tests are the only two FDA-cleared tests to measure Lp-PLA2.

Capabilities and Product Portfolio for Growth

Our extensive capabilities, from development to commercialization, enable our evolution into a multi-product company delivering actionable information to healthcare providers for patient management.

Recent News

March 24, 2015

Diadexus, Inc. Announces Presentation of Results from the PLAC® Activity Test Clinical Validation Study

March 11, 2015

Diadexus, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results